Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb 17;23(2):218-246.
doi: 10.20892/j.issn.2095-3941.2025.0351.

Expert consensus on the detection and clinical application of tumor mutational burden

Zhenying Guo #  1 Chunwei Xu #  2 Shirong Zhang #  3 Yue Hao #  4 Xiaotong Hu  5 Ming Zhao  6 Chan Xiang  7 Yingshi Piao  8 Pingli Sun  9 Xueping Xiang  10 Jing Zhao  11 Huanwen Wu  12 Weixing Li  13 Jinpu Yu  14 Jingping Yuan  15 Shuangshuang Wang  16 Cong Wang  17 Yun Gu  18 Bingjian Lv  19 Liping Zhang  20 Yueping Liu  21 Xiaobin Cui  22 Weizhong Gu  23 Yining Li  24 Wei Wang  25 Wenjun Yang  26 Weiguo Long  27 Jingjing Xiang  28 Hong Mou  29 Biao Liu  30 Huajuan Ruan  31 Yubin Wang  32 Yongjie Zhu  33 Feng Wang  34 Zhonghua Wang  35 Xiaomin Feng  18 Xing Liu  36 Peng Li  37 Min Deng  38 Bin Lian  39 Lili Mao  39 Qian Wang  40 Wenxian Wang  4 Zhengbo Song  4 Ziming Li  41 Wenzhao Zhong  42 Zhijie Wang  43 Shengxiang Ren  44 Wenfeng Fang  45 Yongchang Zhang  46 Jingjing Liu  47 Xiuyu Cai  48 Anwen Liu  49 Wen Li  50 Ping Zhan  51 Hongbing Liu  51 Tangfeng Lv  51 Liyun Miao  52 Lingfeng Min  53 Yu Chen  54 Yu Zhang  55 Feng Wang  56 Zhansheng Jiang  57 Gen Lin  54 Long Huang  49 Xingxiang Pu  58 Rongbo Lin  54 Weifeng Liu  59 Chuangzhou Rao  60 Dongqing Lv  61 Zongyang Yu  62 Peng Shen  63 Xiaoyan Li  64 Chuanhao Tang  65 Chengzhi Zhou  66 Junping Zhang  67 Junli Xue  68 Hui Guo  69 Qian Chu  70 Rui Meng  71 Jingxun Wu  72 Rui Zhang  73 Jin Zhou  74 Zhengfei Zhu  75 Yongheng Li  76 Hong Qiu  70 Fan Xia  75 Yuanyuan Lu  77 Xiaofeng Chen  78 Rui Ge  79 Enyong Dai  80 Yu Han  81 Jian Zhang  82 Yinghua Ji  83 Xianbin Liang  84 Hongmei Zhang  85 Xuelei Ma  85 Xuewen Liu  86 Yu Yao  87 Peng Luo  82 Weiwei Pan  88 Fei Pang  89 Fan Wu  90 Dejian Gu  91 Li Wang  91 Liping Wang  92 Youcai Zhu  93 Li Lin  65 Weiwen Li  94 Xinqing Lin  66 Jing Cai  49 Ling Xu  95 Jisheng Li  96 Xiaodong Jiao  97 Kainan Li  98 Jia Wei  99 Huijing Feng  67 Lin Wang  100 Yingying Du  101 Wang Yao  102 Xuefei Shi  103 Xiaomin Niu  41 Dongmei Yuan  51 Yanwen Yao  51 Yinbin Zhang  69 Binbin Song  104 Wenfeng Li  105 Jianfei Fu  106 Hong Wang  107 Mingxiang Ye  51 Dong Wang  51 Zhaofeng Wang  51 Qing Ji  4 Yuan Fang  108 Qing Wei  4 Zhen Wang  109 Bin Wan  110 Donglai Lv  111 Xiaofeng Li  93 Shengjie Yang  112 Jing Kang  42 Jiatao Zhang  42 Chao Zhang  42 Lin Shi  113 Yina Wang  114 Bihui Li  115 Zhang Zhang  116 Ke Wang  117   118 Zhefeng Liu  107 Nong Yang  46 Lin Wu  58 Xiaobing Chen  119 Gu Jin  120 Zhongwu Li  121 Miao Li  122 Guansong Wang  123 Jiandong Wang  124 Meiyu Fang  4 Yong Fang  125 Xiaojia Wang  4 Jing Chen  71 Yiping Zhang  4 Xixu Zhu  109 Yi Shen  126 Shenglin Ma  127 Biyun Wang  128 Lu Si  39 Yong Song  51 Yuanzhi Lu  129 Aijun Liu  130 Yuchen Han  7
Affiliations

Expert consensus on the detection and clinical application of tumor mutational burden

Zhenying Guo et al. Cancer Biol Med. .

Abstract

As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms. However, the lack of uniformity in detection methods, threshold settings, and reporting formats, as well as the significant differences in TMB values among different cancer types, have hindered the standardized application of this biomarker in clinical practice. This consensus focuses on the definition, standardization of detection, clinical significance, and limitations of TMB, and provides consensus recommendations for the clinical application of TMB in real-world practice in China. This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB, promoting more accurate interpretation of test results, and improving patient care.

Keywords: Biomarkers; targeted panel sequencing; tumor immunotherapy; tumor mutational burden; whole-exome sequencing.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1
Flowchart of TMB testing, including sample preparation, quality control standards for sequencing data, TMB analysis principles, and key factors for TMB result reporting.

References

    1. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8. - PMC - PubMed
    1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. - PMC - PubMed
    1. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. - PMC - PubMed
    1. Xu C, Hao Y, Wang D, Zhang S, Wang W, Wang Q, et al. ECLUNG consensus/guidelines development principles and methods (2024 edition) Intelligent Pharmacy. 2025;3(2):141–2.
    1. Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021;32(12):1626–36. - PubMed

Substances

LinkOut - more resources